Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.

about

Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.

P2860

Q47870600-15FCB095-83AA-4AED-92C0-BEA83B4D7AA1

P2860

Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.

Item

http://www.wikidata.org/entity/Q39010204

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@en

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@nl

type

Item

label

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@en

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@nl

prefLabel

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@en

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@nl

P1476

Palonosetron in combination wi ...... ng paclitaxel and carboplatin.

@en

P2093

Fuminori Ito

http://www.w3.org/2001/XMLSchema#string

Seiji Kanayama

http://www.w3.org/2001/XMLSchema#string

Yasuhito Tanase

http://www.w3.org/2001/XMLSchema#string

P2860

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two p

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.

Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemothe

P2888

s00520-015-2760-3

P304

3317-3322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-2760-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Naoto Furukawa

P577

2015-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25947257

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.

about

P2860

P2860

Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921